Shattuck Labs Inc at Cowen Health Care Conference Transcript
I owe agents of -- we've got quite a panel over there. This is very awkward being on this side. Normally, I'm on that side of the room. It's very awkward being over here. So from Gritstone bio, we have CEO Andrew Allen; from IO Biotech, CEO Mai-Britt Zocca; from Janux Therapeutics, CEO David Campbell; from Shattuck Labs, their CMO Lini Panditel; and then Rob Ross, CEO of Surface; and Rene Russo, CEO of Xilio.
Maybe to start off with just -- IO field had -- you had an explosion of programs in the 2010s, some of which have certainly disappointed. This lead, in many cases, to investors becoming cynical about early-stage IO programs.
Questions & Answers
It's a bit -- just to start off with on a general question for the panel, what -- maybe Andrew will have -- you respond first. But just what do you think the field has learned? How has it changed? And was it now the right time for investors to re-evaluate the IO space and maybe come back to the IO space?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |